Sage's Postpartum Depression Drug Brexanolone Faces Loss-Of-Consciousness Questions

US FDA is recommending a REMS requiring continuous monitoring during the 60-hour infusion and no home use, a potential problem for commercial marketing.

MR  image of Human brain

SAGE Therapeutics Inc.'s postpartum depression drug brexanolone may see its patient population limited by US FDA requirements for continuous monitoring and lack of home use.

If approved, brexanolone, which is purported to be a positive allosteric modulator of GABAA receptors, would be the first therapy...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers